SCHEMBL118688

SCHEMBL118688

COC(=O)c1ccc(S(=O)(=O)Nc2ncc(Cl)cc2Cl)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT1 P17948 1/20 0.55
FLT4 P35916 1/20 0.55
KDR P35968 1/20 0.55
TDP1 Q9NUW8 3/20 0.49
KMT2A Q03164 2/20 0.49
MEN1 O00255 1/20 0.49
KDM4E B2RXH2 4/20 0.48
POLB P06746 3/20 0.48
ALDH1A1 P00352 4/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
TSHR P16473 3/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
MAPT P10636 2/20 0.47
HTT P42858 2/20 0.47
GAA P10253 1/20 0.47
ALOX15 P16050 1/20 0.47
CCR4 P51679 2/20 0.46
CYP2C9 P11712 3/20 0.46
GPR27 Q9NS67 1/20 0.46
ACLY P53396 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL119346 0.89 CYP2C9 (0.51) FLT1FLT4KDRTDP1KMT2A
SCHEMBL120256 0.89 MEN1 (0.54) FLT1FLT4KDRTDP1KMT2A
SCHEMBL121322 0.88 CCR4 (0.47) FLT1FLT4KDRTDP1KMT2A
SCHEMBL119695 0.85 MEN1 (0.71) TDP1KMT2AMEN1KDM4EPOLB
SCHEMBL118204 0.81 TSHR (0.53) FLT1FLT4KDRKMT2AKDM4E
SCHEMBL3160292 0.76 SCN3A (0.52) FLT1FLT4KDRKMT2AKDM4E
SCHEMBL118604 0.74 MEN1 (0.54) TDP1KMT2AMEN1POLBALDH1A1
SCHEMBL4910541 0.74 CCR2 (0.81) CCR4CYP2C9CCR2
SCHEMBL17340511 0.74 ALDH1A1 (0.63) FLT1FLT4KDRTDP1KMT2A
SCHEMBL117883 0.73 MEN1 (0.53) TDP1KMT2AMEN1POLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102427810-A Sulfamoylbenzoic acid derivatives as TRPM8 antagonists RAQUALIA PHARMA INC 2012-04-25 CN disclosed
US-20120094964-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2012-04-19 US disclosed
EP-2424517-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS RaQualia Pharma Inc (JP) 2012-03-07 EP disclosed
WO-2010125831-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2010-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120094964-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS TRPM8, TRPM5, TRPM6 FLT1 3602/4885FLT4 4495/4885KDR 2825/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.